Clinical applications of intravenous immunoglobulins (IVIg) - Beyond immunodeficiencies and neurology

Clinical and Experimental Immunology

Volumn 158, Issue SUPPL. 1, 2009, Pages 23-33

  Hartung, H P ^a   Mouthon, L ^b   Ahmed, R ^c   Jordan, S ^d   Laupland, K B ^e   Jolles, S ^f  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c NEW ENGLAND BAPTIST HOSPITAL   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALGARY   (Canada)

^f UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

Autoimmunity; Immunoglobulin; Sepsis; Transplantation; Vasculitis

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DAPSONE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INSULIN; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; RITUXIMAB; VASOPRESSIN;

ANCA ASSOCIATED VASCULITIS; ANTIINFLAMMATORY ACTIVITY; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASE; BULLOUS PEMPHIGOID; CHORIORETINOPATHY; CLINICAL PRACTICE; CLINICAL TRIAL; CORONARY ARTERY ANEURYSM; DERMATOMYOSITIS; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; EPIDERMOLYSIS BULLOSA ACQUISITA; EPILEPSY; ERYTHROBLASTOPENIA; GRAFT REJECTION; GUILLAIN BARRE SYNDROME; HEMOLYTIC ANEMIA; HLA SYSTEM; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; IMMUNOMODULATION; INCLUSION BODY MYOSITIS; JUVENILE RHEUMATOID ARTHRITIS; MICROSCOPIC POLYANGIITIS; MONOTHERAPY; MUCOCUTANEOUS LYMPH NODE SYNDROME; MUCOUS MEMBRANE PEMPHIGOID; MYASTHENIA GRAVIS; NEUROLOGY; NEUROPATHY; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PLASMAPHERESIS; POLYMYOSITIS; POLYRADICULONEUROPATHY; PRIORITY JOURNAL; REVIEW; SEPSIS; SEPTIC SHOCK; STIFF MAN SYNDROME; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; UNSPECIFIED SIDE EFFECT; WEGENER GRANULOMATOSIS;

AUTOIMMUNE DISEASES; GRAFT REJECTION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFLAMMATION; SEPSIS; SKIN DISEASES, VESICULOBULLOUS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; VASCULITIS;

EID: 72149125317     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2009.04024.x     Document Type: Review

References (83)

1. Imbach P, Barandun S, d'Apuzzo V et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981 1 : 1228 1231.
2. Harvey RD III. The patient: emerging clinical applications of intravenous immunoglobulin. Pharmacotherapy 2005 25 : 85S 93S.
3. Mouthon L. Indications for intravenous immunoglobulins. Presse Med 2006 35 : 714 719.
4. UK Department of Health. Clinical guidelines for immunoglobulin use, 2nd edn. Available at: http://www.dh.gov.uk/en/Publicationsandstatistics/ Publications/PublicationsPolicyAndGuidance/DH-085235 (accessed 22 July 2009).
5. Mydlarski PR, Ho V, Shear NH. Canadian consensus statement on the use of intravenous immunoglobulin therapy in dermatology. J Cutan Med Surg 2006 10 : 205 221.
6. Robinson P, Anderson D, Brouwers M et al. Evidence-based guidelines on the use of intravenous immune globulin for hematologic and neurologic conditions. Transfus Med Rev 2007 21 : S3 8.
7. Australian Health Ministers' Conference. Criteria for the clinical use of intravenous immunoglobulin in Australia. Available at: http://www.nba.gov.au/ ivig/pdf/criteria-qrg.pdf. (accessed 22 July 2009).
8. Oates-Whitehead RM, Baumer JH, Haines L et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 2003 CD004000.
9. Furusho K, Sato K, Soeda T et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1983 2 : 1359.
10. Furusho K, Kamiya T, Nakano H et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984 2 : 1055 1058.
11. Newburger JW, Takahashi M, Gerber MA et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004 110 : 2747 2771. (Pubitemid 39453026)
12. Van der Woude FJ, Rasmussen N, Lobatto S et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985 1 : 425 429.
13. Jayne DR, Davies MJ, Fox CJ et al. Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 1991 337 : 1137 1139.
14. Jayne DR, Lockwood CM Pooled intravenous immunoglobulin in the management of systemic vasculitis. Adv Exp Med Biol 1993 336 : 469 472.
15. Richter C, Schnabel A, Csernok E et al. Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol 1995 101 : 2 7.
16. Levy Y, Sherer Y, George J et al. Serologic and clinical response to treatment of systemic vasculitis and associated autoimmune disease with intravenous immunoglobulin. Int Arch Allergy Immunol 1999 119 : 231 238.
17. Jayne DR, Chapel H, Adu D et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. Q J Med 2000 93 : 433 439.
18. Martinez V, Cohen P, Pagnoux C et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum 2008 58 : 308 317.
19. Ahmed AR. Drug therapy of pemphigus vulgaris. G Ital Dermatol Venereol 2007 142 : 391 408.
20. Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol 2003 139 : 1051 1059.
21. Ahmed AR. Use of intravenous immunoglobulin therapy in autoimmune blistering diseases. Int Immunopharmacol 2006 6 : 557 558.
22. Daoud YJ, Amin KG. Comparison of the cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases. Int Immunopharmacol 2006 6 : 600 606.
23. Ahmed AR, Spigelman Z, Cavacini LA et al. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006 355 : 1772 1779. (Pubitemid 44631360)
24. Jordan S, Cunningham-Rundles C, McEwan R. Utility of intravenous immune globulin in kidney transplantation: efficacy, safety and cost implications. Am J Transplant 2003 3 : 653 664.
25. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969 280 : 735 739.
26. Gerbase-DeLima M, Campos EF, Tedesco-Silva H et al. Anti-HLA class II antibodies and chronic allograft nephropathy. Clin Transpl 2006 201 205.
27. Jordan SC, Pescovitz MD. Presensitization: the problem and its management. Clin J Am Soc Nephrol 2006 1 : 421 432.
28. Jordan SC, Vo A, Tyan D et al. Desensitization therapy with intravenous gammaglobulin (IVIG): applications in solid organ transplantation. Trans Am Clin Climatol Assoc 2006 117 : 199 211.
29. Jordan SC, Tyan D, Stablein D et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly-HLA sensitized adult patients with end stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004 15 : 3256 3262.
30. Zachary AA, Montgomery RA, Leffell MS. Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin. Hum Immunol 2005 66 : 364.
31. Reinsmoen NL, Lai CH, Vo A et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 2008 86 : 820 825.
32. Vieira CA, Agarwal A, Book BK et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: safety, pharmocodynamics and pharmacokinetics. Transplantation 2004 77 : 542 548.
33. Faguer S, Kamar N, Guilbeaud-Frugier C et al. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 2007 83 : 1277 1280.
34. Salama AD, Pursey CD. Drug insight: rituximab in renal disease in transplantation. Nat Clin Pract Nephrol 2006 2 : 221 230.
35. Vo AA, Lukovsky M, Toyoda M et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008 359 : 242 251.
36. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992 20 : 864 874.
37. Martin GS, Mannino DM, Eaton S et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003 348 : 1546 1554.
38. Hofhuis JG, Spronk PE, van Stel HF et al. The impact of severe sepsis on health-related quality of life: a long-term follow-up study. Anesth Analg 2008 107 : 1957 1964.
39. Laupland KB, Zygun DA, Doig CJ et al. One-year mortality of bloodstream infection-associated sepsis and septic shock among patients presenting to a regional critical care system. Intens Care Med 2005 31 : 213 219.
40. Angus DC, Linde-Zwirble WT, Lidicker J et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001 29 : 1303 1310.
41. Finfer S, Bellomo R, Lipman J et al. Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intens Care Med 2004 30 : 589 596.
42. Padkin A, Goldfrad C, Brady AR et al. Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Crit Care Med 2003 31 : 2332 2338.
43. Engel C, Brunkhorst FM, Bone HG et al. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intens Care Med 2007 33 : 606 618.
44. Brun-Buisson C, Meshaka P, Pinton P et al. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intens Care Med 2004 30 : 580 588.
45. Cheng B, Xie G, Yao S et al. Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in China. Crit Care Med 2007 35 : 2538 2546.
46. Vincent JL, Sakr Y, Sprung CL et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006 34 : 344 353.
47. Bernard GR, Wheeler AP, Russell JA et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 1997 336 : 912 918.
48. The Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 1987 317 : 659 665.
49. Bone RC, Fisher CJ Jr., Clemmer TP et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987 317 : 653 658.
50. Angus DC, Birmingham MC, Balk RA et al. E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. JAMA 2000 283 : 1723 1730.
51. Abraham E, Reinhart K, Opal S et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003 290 : 238 247.
52. van den Berghe G, Wouters P, Weekers F et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001 345 : 1359 1367.
53. Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001 344 : 699 709.
54. Annane D, Sebille V, Charpentier C et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002 288 : 862 871.
55. Schiffl H, Lang SM, Fischer R. Daily hemodialysis and the outcome of acute renal failure. N Engl J Med 2002 346 : 305 310. (Pubitemid 34438837)
56. Rivers E, Nguyen B, Havstad S et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001 345 : 1368 1377.
57. Dellinger RP, Carlet JM, Masur H et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004 32 : 858 873. (Pubitemid 38344143)
58. Poole D, Bertolini G, Garattini S. Errors in the approval process and post-marketing evaluation of drotrecogin alfa (activated) for the treatment of severe sepsis. Lancet Infect Dis 2009 9 : 67 72.
59. Sprung CL, Annane D, Keh D et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008 358 : 111 124.
60. Palevsky PM, Zhang JH, O'Connor TZ et al. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 2008 359 : 7 20.
61. Russell JA, Walley KR, Singer J et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008 358 : 877 887.
62. Dellinger RP, Levy MM, Carlet JM et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008 36 : 296 327.
63. Casadevall A. Antibody-based therapies for emerging infectious diseases. Emerg Infect Dis 1996 2 : 200 208.
64. Casadevall A, Scharff MD. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother 1994 38 : 1695 1702.
65. Norrby-Teglund A, Haque KN, Hammarstrom L. Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis. J Intern Med 2006 260 : 509 516.
66. Alejandria MM, Lansang MA, Dans LF. Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev 2002 1 : CD001090.
67. Pildal J, Gotzsche PC. Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. Clin Infect Dis 2004 39 : 38 46.
68. Neilson AR, Burchardi H, Schneider H. Cost-effectiveness of immunoglobulin M-enriched immunoglobulin (Pentaglobin) in the treatment of severe sepsis and septic shock. J Crit Care 2005 20 : 239 249.
69. Turgeon AF, Hutton B, Fergusson DA et al. Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med 2007 146 : 193 203.
70. Laupland KB, Kirkpatrick AW, Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med 2007 35 : 2686 2692.
71. Kreymann KG, de Heer G, Nierhaus A et al. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med 2007 35 : 2677 2685.
72. Werdan K, Pilz G, Bujdoso O et al. Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit Care Med 2007 35 : 2693 2701.
73. Hentrich M, Fehnle K, Ostermann H et al. IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple-center trial. Crit Care Med 2006 34 : 1319 1325.
74. Werdan K. Mirror, mirror on the wall, which is the fairest meta-analysis of all? Crit Care Med 2007 35 : 2852 2854.
75. Neugebauer EA. To use or not to use? Polyclonal intravenous immunoglobulins for the treatment of sepsis and septic shock. Crit Care Med 2007 35 : 2855 2856.
76. Leichtman AB, Cohen D, Keith D et al. Kidney and pancreas transplantation in the United States, 1997-2006: the HRSA Breakthrough Collaboratives and the 58 DSA Challenge. Am J Transplant 2008 8 : 946 957.
77. Finfer S, Bellomo R, Boyce N et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004 350 : 2247 2256. (Pubitemid 38669207)
78. Pilz G, Appel R, Kreuzer E et al. Comparison of early IgM-enriched immunoglobulin vs polyvalent IgG administration in score-identified postcardiac surgical patients at high risk for sepsis. Chest 1997 111 : 419 426.
79. Laupland KB, Boucher P, Rotstein C et al. Intravenous immunoglobulin for severe infections: a survey of Canadian specialists. J Crit Care 2004 19 : 75 81.
80. Valiquette L, Low DE, Chow R et al. A survey of physician's attitudes regarding management of severe group A streptococcal infections. Scand J Infect Dis 2006 38 : 977 982.
81. Ohlsson A, Lacy JB. Intravenous immunoglobulin for suspected or subsequently proven infection in neonates. Cochrane Database Syst Rev 2004 1 : CD001239.
82. National Perinatal Epidemiology Unit (NPEU). INIS: International Neonatal Immunotherapy Study. Available at: http://www.npeu.ox.ac.uk/inis (accessed 25 June 2009).
83. Jayne DR, Lockwood CM. Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol 1996 35 : 1150 1153.